Tests cadonilimab with chemotherapy before chemoradiotherapy for locally advanced cervical cancer
Tests cadonilimab with chemotherapy, then chemoradiotherapy, in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07400536, who can take part
Where in China
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT07400536
- Record updated
- 13 May 2026
- Original description
This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.Read full original descriptionShow less
A Phase III, Multicenter, Open-label, Randomized Controlled Clinical Study on the Treatment of Locally Advanced Cervical Cancer With Cadonilimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy
This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.
Inclusion: To be enrolled, subjects had to meet all of the following criteria:; Female, aged 18-70 years (inclusive of cutoff values); Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix; Patients with stage IIB-IVA cervical cancer (FIGO stage 2018) who had not received any previous antineoplastic therapy; At least one measurable lesion according to RECIST v1.1; Eastern Cooperative Oncology Group (ECOG) performance-status score 0-1; Have adequate organ function.
Exclusion: Had received any previous antineoplastic therapy, including but not limited to surgery (except biopsy), radiotherapy, or systemic therapy (chemotherapy, immunotherapy, targeted therapy); Distant metastatic disease (including inguinal lymph node metastasis and lymph node metastasis above the level of the superior edge of the L1 pyramid in the proximal cephalic region, according to FIGO 2018 stage IVB); Had any condition that was deemed by other investigators to be ineligible for participation in the trial; Subjects were excluded from the study if they met any of the following criteria:; He had undergone total hysterectomy (removal of the corpus uteri and cervix); Inability to undergo brachytherapy or refusal to undergo brachytherapy for reasons such as anatomical abnormalities.